ConductScience.org, home

Comparison · NCT01416636-2ee8e26e

High Dose vs Low Dose: Number of Participants With Clinical Worsening

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. High Dose vs Low Dose: Number of Participants With Clinical Worsening. Trial comparisons, record NCT01416636-2ee8e26e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01416636-2ee8e26e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1320.06550.248wilson
Risk in group 20.2310.1370.361wilson
Risk difference, group 1 minus group 2-0.0987-0.2450.0506newcombe hybrid score
Risk ratio, group 1 over group 20.5720.2451.34log
Odds ratio, group 1 over group 20.5070.1821.41log
Number needed to treat, for one fewer participant with the outcome on High Dose than on Low Dose10.1from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1High DoseTreprostinil sodium high dose753OG000
Group 2Low DoseTreprostinil sodium low dose1252OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Clinical Worsening
Description
Clinical worsening defined as a decrease of 6-minute walk test distance of more than 20% from baseline due to Chronic Thromboembolic Pulmonary Hypertension, decrease of New York Heart Association functional class, hospitalization with the requirement for additional Pulmonary Hypertension specific treatment and/or death due to worsening Chronic Thromboembolic Pulmonary Hypertension.~Clinical Worsening was assessed after 12 weeks and 24 weeks, participants experiencing clinical worsening at any time-point are reported.
Time frame
12 weeks and 24 weeks
Population
All randomized subjects who received at least one dose of study medication.

Source ClinicalTrials.gov

Trial

Title
Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)
NCT number
NCT01416636
Phases
PHASE3
Conditions
Non-operable Chronic Thromboembolic Pulmonary Hypertension
Interventions
Treprostinil sodium
Lead sponsor
SciPharm SàRL
Results first posted
2019-06-10

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01416636-2ee8e26e